Mural Oncology (MURA)
| Bid | 3.31 |
| Market Cap | 58.01M |
| Revenue (ttm) | 2.62M |
| Net Income (ttm) | -154.06M |
| EPS (ttm) | -9.02 |
| PE Ratio (ttm) | -0.38 |
| Forward PE | -0.82 |
| Analyst | Buy |
| Ask | 3.73 |
| Volume | 129,066 |
| Avg. Volume (20D) | 169,410 |
| Open | 3.67 |
| Previous Close | 3.68 |
| Day's Range | 3.40 - 3.70 |
| 52-Week Range | 2.87 - 5.62 |
| Beta | 3.69 |
About MURA
Mural Oncology Plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops engineered interleukin-18 and tumor-targeted interleukin-12 programs. The company was inco...
Analyst Forecast
According to 5 analyst ratings, the average rating for MURA stock is "Buy." The 12-month stock price forecast is $16, which is an increase of 370.59% from the latest price.
12 months ago · seekingalpha.com
Recent Spin Mural Oncology At An Attractive Discount To Cash And Portfolio ValueMural Oncology trades at approximately $5, a material discount to cash holdings of over $16/share, as reported in November 2023. The pipeline of 3 major candidates of cytokine cancer therapies at diff...
